(Q45227683)

11 December 2017

title

Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression (English)

1 reference

11 December 2017

1 reference

1 reference

Kraus MR

1

1 reference

11 December 2017

Schäfer A

series ordinal

2

1 reference

11 December 2017

Al-Taie O

series ordinal

3

1 reference

11 December 2017

Scheurlen M

series ordinal

4

1 reference

11 December 2017

publication date

1 January 2005

1 reference

Journal of Viral Hepatitis

11 December 2017

published in

1 reference

11 December 2017

volume

12

1 reference

11 December 2017

issue

1

1 reference

11 December 2017

page(s)

96-100

1 reference

Epidemiology of hepatitis C

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00554.X

Hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00554.X

Pegylated interferons for the treatment of chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00554.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00554.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00554.X

Paroxetine for the prevention of depression induced by interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00554.X

Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00554.X

Side effects of therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00554.X

A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00554.X

Paroxetine for the prevention of depression induced by high-dose interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00554.X

Incidence, pathoetiology and treatment of interferon-alpha induced neuro-psychiatric side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00554.X

International experiences with the Hospital Anxiety and Depression Scale--a review of validation data and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00554.X

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00554.X

Treatment of cytokine-induced depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00554.X

A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00554.X

An open-label trial of citalopram for major depression in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00554.X

Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00554.X

10.1111/J.1365-2893.2005.00554.X

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference